Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented preclinical data showing its proprietary ...

Neuroendocrine tumors (NETs) are difficult to treat due to their high heterogeneity and complexity. SEZ6 (Seizure-related 6 homolog) is a key regulator of dendritic formation and neural signaling and ...

Akari Therapeutics (AKTX) announced the presentation of immune mechanism-of-action data for its novel ADC payload, PH1. The Company will host a live webcast to discuss the presented data on Tuesday, ...

Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to deliver ...